NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY

INTRODUCTION: Severe Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurs in ~ 30% of Diffuse Large B Cell Lymphoma (DLBCL) patients treated with CAR-T cell therapy. The current treatment for severe ICANS is glucocorticoids, and this may be combined with tocilizumab for concurrent c...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Mokhtari, Sepideh, Asquith, Justin, Bachmeier, Christina, Faramand, Rawan, Kim, Youngchul, Peguero, Edwin, Sahebjam, Solmaz, Jain, Michael, Vogelbaum, Michael, Davila, Marco, Forsyth, Peter, Locke, Frederick, Aleksandr, Lazaryan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Neurological Complications of Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651408/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.538
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi